Wednesday, August 5, 2020

Avacta Group partners with Swiss life sciences firm

Avacta Group, the biopharma business based in Wetherby and Cambridge, has partnered with Swiss life sciences company Selexis to develop a clinical candidate to human trials.

Together, the two companies will develop the Chinese hamster ovary cell line that will be used to manufacture Avacta’s first Affirmer clinical candidate for first-time-in-human clinical trials.

Avacta says this “major milestone” means its on track to submit applications for an Affirmer PD-L1 inhibitor for investigational new drug application and clinical trial approval by the end of 2020.

Avacta’s first clinical candidate will be against PD-L1, a clinically validated immune checkpoint that plays an important role in the tumour escape mechanism in cancer.

The lead molecule (AVA004) is a potent PD-L1 antagonist that has been engineered with an Fc domain for half-life extension.

Avacta has demonstrated the preclinical efficacy of AVA004 in syngeneic and xenograft mouse models and it compares favourably to approved monoclonal antibodies such as Imfinzi, Tecentriq and Bavencio at the doses administered.

“The strategic partnership with Selexis allows Avacta to access the technology and know-how to develop high-expressing CHO cell lines as well as the extensive experience of developing a range of Fc fusion proteins for clinical manufacturing,” said Alastair Smith, Avacta Group CEO.

“These cell lines are the essential basis of clinical manufacturing of AVA004 and this partnership supports Avacta’s strategy to demonstrate safety and tolerability of the Affimer platform in humans with a planned IND/CTA by the end of 2020.

“The ultimate aim is to combine AVA004 with other Affimer checkpoint modulators in bispecific cancer immunotherapies, and with novel chemotherapies as drug conjugates and combination therapies utilising proprietary tumour microenvironment targeting chemistry.

“These approaches seek to combine modulation of the adaptive immune response with stimulation of the innate immune system, with the aim of improving the clinical outcome for the sizeable proportion of solid tumour patients having “cold” tumours that do not respond to checkpoint inhibitors alone.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £31.50 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.




Latest news

Plans for tourism destination at Lincolnshire golf course approved

Plans for a major tourism destination on a Lincolnshire golf course will deliver a significant boost to the region’s local economy and tourist sector,...

ABP deal sees British Steel resume control of Immingham Bulk Terminal

British Steel has resumed operation control of Immingham Bulk Terminal (IBT) after completing a deal with Associated British Ports (ABP). The facility operated by British...

Revenue rise for electronics manufacturer

Filtronic, the AIM-listed Shipley-based electronics manufacturer, has reported a rise in revenue in full-year results released this week. For the year ended 31 May 2020,...

Discretionary Grant Fund reopens to COVID-hit Leeds SMEs

Leeds-based SMEs and charities in Leeds affected by COVID-19 are being urged to apply for support as the Discretionary Grant Fund (DGF) reopens for...

SME manufacturing activity falls at record pace

SME manufacturing output volumes fell at the fastest rate on record (since October 1988), according to the latest quarterly CBI SME Trends Survey. The survey...

Lockdown leads to sales surge for Gelder’s online business

The COVID-19 lockdown has delivered a sales surge for Lincolnshire-based Gelder Group’s online business, LoveDIY. Amongst the thousands of tins of emulsion, 844 tins of...

Related news

Plans for tourism destination at Lincolnshire golf course approved

Plans for a major tourism destination on a Lincolnshire golf course will deliver a significant boost to the region’s local economy and tourist sector,...

ABP deal sees British Steel resume control of Immingham Bulk Terminal

British Steel has resumed operation control of Immingham Bulk Terminal (IBT) after completing a deal with Associated British Ports (ABP). The facility operated by British...

Revenue rise for electronics manufacturer

Filtronic, the AIM-listed Shipley-based electronics manufacturer, has reported a rise in revenue in full-year results released this week. For the year ended 31 May 2020,...

Discretionary Grant Fund reopens to COVID-hit Leeds SMEs

Leeds-based SMEs and charities in Leeds affected by COVID-19 are being urged to apply for support as the Discretionary Grant Fund (DGF) reopens for...

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close